Xintela's XSTEM demonstrates safety and efficacy two years after knee osteoarthritis treatment

Xintela reports positive results from its Phase I/IIa study with the stem cell product XSTEM for moderate knee osteoarthritis, where the treatment was safe with no serious side effects. The study in 24 patients in Australia showed that the highest dose (16 million stem cells) provided 57 percent pain relief according to VAS and improved knee function according to KOOS, with effects that were maintained for 24 months. The results also indicate improved bone structure and a trend towards reduced cartilage degradation, suggesting disease-modifying potential. Xintelas CSO Lucienne Vonk highlights the long-term effect as an improvement in patients' quality of life. The company is now planning partnerships for further studies and commercialization.